Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing ...
Clinical Trials Arena on MSN
Trials to watch: Three major catalysts in Alzheimer’s disease
While Lilly and Eisai/Biogen have validated the amyloid theory, there is an unmet need for drugs with alternative mechanisms ...
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 ...
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
In patients with moderate-to-severe allergic rhinoconjunctivitis induced by house dust mites, subcutaneous allergen immunotherapy is effective and generally well tolerated.
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
6d
Merck & Co., Inc. (MRK) Received FDA Approval For Keytruda Qlex, Cutting Infusion Time to 2 Minutes
This month, the FDA approved Keytruda Qlex, a subcutaneous version of the drug that can be administered in just one to two minutes, compared to the 30-minute intravenous infusion.
A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight ...
The weekly combination therapy is intended for adults with poor glucose control despite basal insulin or GLP-1 receptor ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and ...
The FDA has approved Keytruda Qlex, a faster, under-the-skin cancer treatment offering convenience and flexibility. Here's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback